GlassScriptPhysician profile
Mohamad Altriki
NPI 1619061736
$3,554.92
in general payments reported to CMS, 2019-2025
25 companies · $902 in 2025
The $902 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $359 · 2021: $398 · 2022: $59.45 · 2023: $334 · 2024: $655 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.29 |
| Education | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $981.10 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $747.41 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $272.40 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $225.56 | 2021-2025 | |
| Vifor Pharma, INC. | $182.43 | 2019-2025 | Veltassa, Korsuva |
| Ardelyx, INC. | $154.56 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $154.10 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.97 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $97.20 | 2019 | |
| Aurinia Pharma U.S., INC. | $82.70 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $78.23 | 2024-2025 | Tarpeyo |
| Amgen INC. | $55.67 | 2019-2025 | Tavneos |
| Ani Pharmaceuticals, INC. | $53.93 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $43.43 | 2021-2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $41.72 | 2021-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.76 | 2019-2022 | |
| Horizon Therapeutics Plc | $37.18 | 2019-2020 | |
| Medtronic, INC. | $27.79 | 2025 | Symplicity G3 |
| Novo Nordisk INC | $22.65 | 2024 | Ozempic |
| Alexion Pharmaceuticals, INC. | $21.88 | 2024 | Ultomiris |
| Genzyme Corporation | $19.38 | 2019 | |
| Travere Therapeutics, INC. | $19.26 | 2024-2025 | Filspari |
| Bard Peripheral Vascular, INC. | $15.86 | 2024 | |
| Fresenius USA Marketing, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Altriki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.